Last reviewed · How we verify
14C-microtracer
At a glance
| Generic name | 14C-microtracer |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body (PHASE1)
- A Study to Test How BI 1819479 is Taken up and Processed by the Body (PHASE1)
- A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults (PHASE1)
- AZD5305 hADME in Patients With Advanced Solid Malignancies (PHASE1)
- A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults (PHASE1)
- Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) (PHASE1)
- A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants (PHASE1)
- A Study to Learn How the Study Medicine Called [14C]PF-07054894 is Processed by the Body (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 14C-microtracer CI brief — competitive landscape report
- 14C-microtracer updates RSS · CI watch RSS
- Sanofi portfolio CI